We are rapidly transitioning to an innovation and R&D-driven pharmaceutical company, leveraging our leading manufacturing and commercial capabilities to achieve our mission of “providing today’s patients with medicines of the future” . We have established three R&D centers in Nanjing, Shanghai and Boston, respectively. With the approval of the Ministry of Science and Technology, we have also established a national key laboratory of translational medicine and innovative pharmaceuticals . We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China ” and “Top 100 Pharmaceutical Manufacturing Enterprises of China ”.

Milestones

1995
2001
2003
2006
2007
2013
2015
2018
2019
2020

established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals
acquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals,
built our own research and development team
acquired the entire equity interest in Simcere Dongyuan, established postdoctoral research station
acquired a controlling interest in Shandong Simcere
became the first bio and chemical pharmaceutical company in China to be listed on the NYSE
completed the privatization
established the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals approved by the Ministry of Science and Technology
Shanghai R&D center established
Boston R&D Center established
Listed on HKEX

1995
established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals
2001
cquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals, built our own research and development team
2003
acquired the entire equity interest in Simcere Dongyuan, established postdoctoral research station
2006
acquired a controlling interest in Shandong Simcere
2007
became the first bio and chemical pharmaceutical company in China to be listed on the NYSE
2013
completed the privatization
2015
established the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals approved by the Ministry of Science and Technology
2018
Shanghai R&D center established
2019
Boston R&D Center established
2020
Listed on HKEX

Management Team

: Mr. Ren Jinsheng

Executive Director and Chairman of the Board , Chief Executive Officer

: Mr. Wan Yushan

Executive Director of the Board and Chief Financial Officer

: Dr. Tang Renhong

Executive Director of the Board and Executive Vice President

: Dr. Wang Pin

Chief Scientific Officer

: Dr. Kevin Oliver

Senior Vice President

: Mr. Cheng Xianghua

Vice President

: Dr. Qian Haibo

Vice President

: Dr. Shi Ruiwen

Vice President

: Dr. Wang Feng

Vice President

Mission

Providing Today’s Patients with Medicines of the Future

Core Values

: Integrity

: Excellence

: Perseverance

: Proactivity

: Customer-First

Simcere CI

The name “Simcere” comes from the word “sincere”, which embodies our main principle of treating people with sincerity.
On the left side of our logo is Simcerer running against the wind, representing the spirit of unremitting endeavor and the encourage to pursue excellence.
The color green symbolizes life, health and vitality.

Milestones

Management Team

Mr. Ren Jinsheng

Mr. Wan Yushan

Dr. Tang Renhong

Dr. Wang Pin

Dr. Kevin Oliver

Mr. Cheng Xianghua

Dr. Qian Haibo

Dr. Shi Ruiwen

Dr. Wang Feng

Mission

Providing Today’s Patients with Medicines of the Future

Core Values

Simcere CI